N/A
N=943
Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis
Multiple Myeloma
Bottom Line
View on ClinicalTrials.gov: NCT03506386 ↗Enrolled (actual)
943
Serious AEs
—
Results posted
Feb 2021
Primary outcome: Primary: Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics — 342; 366; 48; 36 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No Intervention (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Takeda
- Primary completion
- Nov 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics |
342; 366; 48; 36; 232; 241 | — |
| PRIMARY Number of Multiple Myeloma (MM) Participants Categorized by Treatment Patterns |
394; 456; 66; 3; 14; 0 | — |
| SECONDARY Overall Survival (OS) |
1926; 3277; 1566 | < 0.0001 sig |
| SECONDARY Duration of Treatment |
5; 4.2; 3.6; 2.3; 2.8; 1.8 | — |
Summary
The purpose of this study is to present a descriptive analysis of demographic and clinical characteristics of the participants, as well as of the treatment patterns for multiple myeloma (MM) in Brazil.
Eligibility Criteria
Inclusion Criteria
- Provision of written informed consent, for participants who are alive and not lost to follow-up (for participants already deceased or lost follow up, informed consent should have been waived by the corresponding ethics review board [ERB]).
- Documented diagnosis of MM by the responsible physician between January 1, 2008, and December 31, 2016.
- Absence of any plasma-cell disorder other than MM.
- Absence of any immunoglobulin-related disorder other than MM.
Data sourced from ClinicalTrials.gov (NCT03506386). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.